Literature DB >> 21178406

Fungal x host interactions in Chromoblastomycosis: what we have learned from animal models and what is yet to be solved.

Claudio Guedes Salgado.   

Abstract

Animal studies with chromoblastomycosis were initiated together with the first descriptions of the disease. In this editorial commentary, animal models are briefly reviewed, and the available data based on new immunology tools are discussed.

Entities:  

Mesh：

Year:  2010        PMID： 21178406      PMCID： PMC3080194          DOI： 10.4161/viru.1.1.10169

Source DB:  PubMed          Journal:  Virulence        ISSN： 2150-5594            Impact factor:   5.882


  21 in total

1.  Experimental studies on chromoblastomycosis.

Authors:  R D AZULAY
Journal:  J Invest Dermatol       Date:  1945       Impact factor: 8.551

2.  Development of natural culture media for rapid induction of Fonsecaea pedrosoi sclerotic cells in vitro.

Authors:  Moises Batista da Silva; Jorge Pereira da Silva; Suellen Sirleide Pereira Yamano; Ubirajara Imbiriba Salgado; José Antonio Picanço Diniz; Claudio Guedes Salgado
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

3.  A case of chromoblastomycosis in a horse.

Authors:  J G Simpson
Journal:  Vet Med Small Anim Clin       Date:  1966-12

4.  Prolonged infection by Fonsecaea pedrosoi after antigenic co-stimulation at different sites in experimental murine chromoblastomycosis.

Authors:  Alexandre Paulo Machado; Maria Regina Regis Silva; Olga Fischman
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

5.  Cytokines and lymphocyte proliferation in patients with different clinical forms of chromoblastomycosis.

Authors:  Viviane Mazo Fávero Gimenes; Maria Da Glória de Souza; Karen Spadari Ferreira; Sirley G Marques; Azizedite Guedes Gonçalves; Daniel Vagner de Castro Lima Santos; Conceição de Maria Pedroso e Silva; Sandro Rogério Almeida
Journal:  Microbes Infect       Date:  2005-03-21       Impact factor: 2.700

6.  Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial efficacy of phagocytes.

Authors:  Daniela S Alviano; Anderson J Franzen; Luiz R Travassos; Carla Holandino; Sonia Rozental; Regina Ejzemberg; Celuta S Alviano; Marcio L Rodrigues
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  The cell-mediated immune reaction in the cutaneous lesion of chromoblastomycosis and their correlation with different clinical forms of the disease.

Authors:  Solange Corrêa Garcia Pires d'Avila; Carla Pagliari; Maria Irma Seixas Duarte
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

8.  Chromomycosis in the toad (Bufo marinus) and a comparison of the etiologic agent with fungi causing human chromomycosis.

Authors:  L F Velasquez; A Restrepo
Journal:  Sabouraudia       Date:  1975-03

9.  Cell-mediated immune responses in mice infected with Fonsecaea pedrosoi.

Authors:  N Kurita
Journal:  Mycopathologia       Date:  1979-08-31       Impact factor: 2.574

10.  Experimental murine chromomycosis mimicking chronic progressive human disease.

Authors:  J Ahrens; J R Graybill; A Abishawl; F O Tio; M G Rinaldi
Journal:  Am J Trop Med Hyg       Date:  1989-06       Impact factor: 2.345
View more
  7 in total

1.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 2.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Pathogenicity and Growth Conditions Modulate Fonsecaea Extracellular Vesicles' Ability to Interact With Macrophages.

Authors:  Lucas de Oliveira Las-Casas; Clara Luna Freitas Marina; Raffael Júnio Araújo de Castro; Luísa Coutinho Coelho; Sônia Nair Báo; G Sybren de Hoog; Vânia Aparecida Vicente; Larissa Fernandes; Anamelia Lorenzetti Bocca
Journal:  Front Cell Infect Microbiol       Date:  2022-06-09       Impact factor: 6.073

Review 4.  Chromoblastomycosis.

Authors:  Paweł M Krzyściak; Małgorzata Pindycka-Piaszczyńska; Michał Piaszczyński
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

5.  Modulation of the immune response by Fonsecaea pedrosoi morphotypes in the course of experimental chromoblastomycosis and their role on inflammatory response chronicity.

Authors:  Isaque Medeiros Siqueira; Raffael Júnio Araújo de Castro; Luiza Chaves de Miranda Leonhardt; Márcio Sousa Jerônimo; Aluízio Carlos Soares; Tainá Raiol; Christiane Nishibe; Nalvo Almeida; Aldo Henrique Tavares; Christian Hoffmann; Anamelia Lorenzetti Bocca
Journal:  PLoS Negl Trop Dis       Date:  2017-03-29

6.  A Model for Trans-Kingdom Pathogenicity in Fonsecaea Agents of Human Chromoblastomycosis.

Authors:  Gheniffer Fornari; Renata Rodrigues Gomes; Juliana Degenhardt-Goldbach; Suelen Silvana Dos Santos; Sandro Rogério de Almeida; Germana Davila Dos Santos; Marisol Dominguez Muro; Cleusa Bona; Rosana Herminia Scola; Edvaldo S Trindade; Israel Henrique Bini; Lisandra Santos Ferreira-Maba; Daiane Rigoni Kestring; Mariana Machado Fidelis do Nascimento; Bruna Jacomel Favoreto de Souza Lima; Morgana F Voidaleski; Douglas André Steinmacher; Bruna da Silva Soley; Shuwen Deng; Anamelia Lorenzetti Bocca; Moises B da Silva; Claudio G Salgado; Conceição Maria Pedroso E Silva de Azevedo; Vania Aparecida Vicente; Sybren de Hoog
Journal:  Front Microbiol       Date:  2018-10-09       Impact factor: 5.640

7.  Muriform Cells Can Reproduce by Dividing in an Athymic Murine Model of Chromoblastomycosis due to Fonsecaea pedrosoi.

Authors:  Bilin Dong; Wei Liu; Ruoyu Li; Yao Chen; Zhongsheng Tong; Xu Zhang; Liuqing Chen; Dongsheng Li
Journal:  Am J Trop Med Hyg       Date:  2020-06-04       Impact factor: 2.345
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.